Medicine and Dentistry
Surgery
100%
Soft Tissue Sarcoma
88%
Diseases
74%
Neoplasm
71%
Pancreas Cancer
67%
Chemoradiotherapy
65%
Recurrent Disease
63%
Pancreaticoduodenectomy
59%
Radiation Therapy
49%
Overall Survival
45%
Pancreas Adenocarcinoma
44%
Malignant Neoplasm
40%
Adenocarcinoma
38%
Prognostic Factor
27%
Neoadjuvant Therapy
27%
Gastrointestinal Stromal Tumor
25%
Metastatic Carcinoma
25%
Survival Rate
22%
Adjuvant Therapy
21%
Connective Tissue Cancer
18%
Gemcitabine
18%
Imatinib
18%
Pancreatectomy
17%
Retroperitoneal Sarcoma
15%
Cancer
14%
Surgeon
14%
Abdominal Cancer
14%
Surgical Margin
13%
Disease Specific Survival
13%
Disease Free Survival
13%
Lymph Node
10%
Gastroesophageal Junction
10%
External Beam Radiotherapy
10%
Multivariate Analysis
10%
Carcinoma
9%
Fluorouracil
9%
Preoperative Radiotherapy
9%
Superior Mesenteric Artery
9%
Doxorubicin
8%
Stomach Adenocarcinoma
8%
Systemic Therapy
8%
Multimodality Cancer Therapy
8%
Computer Assisted Tomography
8%
Stomach Carcinoma
8%
Hazard Ratio
7%
Induction Chemotherapy
7%
Cancer Staging
7%
Endoscopic Ultrasound
7%
Postoperative Complication
7%
Oncology
7%
Keyphrases
Soft Tissue Sarcoma
45%
Pancreaticoduodenectomy
38%
Pancreatic Adenocarcinoma
28%
Combined Modality Therapy
27%
Pancreatic Cancer
26%
Overall Survival
25%
Tumor
24%
Resection
22%
Resectable Pancreatic Cancer
21%
Gastrointestinal Stromal Tumor
21%
Surgical Resection
19%
Chemotherapy
19%
Prognostic Factors
19%
Chemoradiation
19%
Radiotherapy
18%
Confidence Interval
17%
Extremity Soft Tissue Sarcoma
17%
Radiation Therapy
16%
Retroperitoneal Sarcoma
15%
Neoadjuvant Therapy
15%
Adjuvant Therapy
15%
Local Recurrence
13%
Preoperative Chemoradiation
13%
Recurrent Disease
13%
Gemcitabine
12%
Disease-specific Survival
12%
Sarcoma
12%
Pancreatic Ductal Adenocarcinoma
11%
Imatinib
11%
Local Control
11%
Treatment Strategy
11%
Neoadjuvant Chemoradiotherapy (nCRT)
11%
Disease-free Survival
11%
Systemic Therapy
11%
Patient Survival
10%
Potentially Resectable
10%
Single Institution
10%
Pathological Complete Response
9%
Metastatic Disease
9%
Locally Recurrent
9%
Median Survival
9%
Tumor Size
9%
Adenocarcinoma
8%
Concurrent Chemoradiotherapy
8%
Pancreatic Head
8%
Phase II Trial
8%
Distant Metastasis
8%
University of Texas
8%
Adjuvant Imatinib
8%
Patient Management
8%